The SCIP platform is an innovative technology that develops modified variants of cell surface proteins in hematopoietic stem cells (HSCs). These modifications allow the cells to maintain their essential functions while resisting depletion from immunotherapies. Furthermore, the platform features paired immunotherapies that selectively target and deplete diseased cells, ensuring that the shielded healthy cells remain unharmed.